September 2021: Aducanumab for Alzheimer's, antibiotics, shared-decision making, and dental health

23:51
 
シェア
 

Manage episode 300745931 series 1426075
著作 BMJ talk medicine and BMJ Group の情報はPlayer FM及びコミュニティによって発見されました。著作権は出版社によって所持されます。そして、番組のオーディオは、その出版社のサーバから直接にストリーミングされます。Player FMで購読ボタンをタップし、更新できて、または他のポッドキャストアプリにフィードのURLを貼り付けます。
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the September issue of DTB. They discuss the US FDA's controversial decision to license aducanumab for Alzheimer's disease (https://dtb.bmj.com/content/59/9/130) and consider barriers to prescribing shorter courses of antibiotics in primary care (https://dtb.bmj.com/content/59/9/131). The editors also highlight the impact that some medicines have on oral health and dental treatment (https://dtb.bmj.com/content/59/9/135). Before all of that though, the recent NICE's guideline on shared decision making. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

3643 つのエピソード